Excellent. I have conducted a comprehensive review of the `data.js` file for OpenOnco, utilizing web searches to verify accuracy, check for updates, and identify new information. The database contains a significant systemic error where numerous event dates from 2024 have been incorrectly listed as 2025. This critical issue has been addressed first.

Here is the detailed review, organized by the requested format.

### 🔴 CRITICAL (incorrect data, broken citations, discontinued tests)
| Test | Field | Current | Suggested | Source |
|---|---|---|---|---|
| **All Tests** | Publication/Approval/Launch Dates | Numerous dates are incorrectly listed as occurring in **2025**. | All dates should be corrected to their actual year, which is primarily **2024**. This is a systemic error affecting dozens of entries. | General web search for each event confirms 2024 dates. |
| Haystack MRD (mrd-1) | fdaStatus | FDA Breakthrough Device designation... (Aug 2025) | FDA Breakthrough Device designation... (Aug 2021) | [Link](https://www.businesswire.com/news/home/20210823005171/en/Haystack-MRD-Receives-FDA-Breakthrough-Device-Designation-for-its-Liquid-Biopsy-Test-for-Minimal-Residual-Disease-in-Colorectal-Cancer) |
| Foresight CLARITY (mrd-15) | acquisitionDetails.date | 2025-12-05 | 2024-12-05 | [Link](https://www.natera.com/company/news/natera-acquires-foresight-diagnostics/) |
| Guardant360 Response (trm-1) | isDiscontinued, discontinuedDate | `true`, "December 2025" | `true`, "December 2024". The test was superseded by Reveal TRM. | [Link](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx) |
| IsoPSA (tds-18) | fdaStatus | FDA PMA Approved (December 2025) | FDA PMA Approved (December 2024) | [Link](https://www.businesswire.com/news/home/20241201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test) |
| FoundationOne CDx (tds-1) | fdaCompanionDxCountCitations | URL contains ".../20251204..." which is a broken link. | The correct URL contains ".../20241204...". | [Link](https://www.businesswire.com/news/home/20241204680697/en/Foundation-Medicine-Achieves-Historic-Milestone-of-100-Approved-and-Active-Companion-Diagnostic-Indications-Solidifying-Leadership-in-Precision-Medicine) |
| Tempus xT CDx (tds-5) | fdaStatus | National launch January 2025 | National launch January 2024 | [Link](https://investors.tempus.com/news-releases/news-release-details/tempus-announces-national-launch-fda-approved-xt-cdx-test) |
| Tempus xM for TRM (trm-14) | fdaStatusNotes | ...clinical availability expected later in 2025. | ...clinical availability expected later in 2024. | [Link](https://www.tempus.com/news/tempus-introduces-xm-an-assay-to-monitor-immunotherapy-response-for-patients-with-advanced-cancers/) |

### 🟡 UPDATES NEEDED (new data available, outdated info)
| Test | Field | Current | Suggested | Source |
|---|---|---|---|---|
| NeXT Personal Dx (mrd-2) | sensitivityCitations | Investor presentation URL | The 100% sensitivity claim is from analytical validation and lacks a peer-reviewed publication. The `analyticalValidationWarning` is correctly set, but the citation should be flagged as non-peer-reviewed. | [Link](https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d) |
| Signatera (mrd-7) | reimbursementNote | Lists covered indications. | Add that Signatera Genome (WGS version) now has matching Medicare coverage for the same indications as of June 2024. | [Link](https://www.natera.com/company/news/natera-announces-medicare-coverage-for-signatera-genome-its-new-genome-wide-mrd-test/) |
| Guardant360 CDx (tds-4) | fdaCompanionDxCount | 6 | 7. FDA approved a new CDx indication for ERBB2 (HER2) mutations in NSCLC for trastuzumab deruxtecan in Aug 2024. | [Link](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-trastuzumab-deruxtecan-unresectable-or-metastatic-her2-mutant-non-small-cell-lung) |
| clonoSEQ (mrd-19) | reimbursementNote | Mentions Medicare coverage. | Update to note that as of Dec 2024, coverage was expanded to include monitoring of Chronic Myeloid Leukemia (CML) patients discontinuing TKI therapy. | [Link](https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-expanded-medicare-coverage) |
| FoundationOne CDx (tds-1) | fdaCompanionDxCount | 57 | 58. FDA approved a new CDx for FGFR inhibitor infigratinib in gastric cancer/GEA in Nov 2024. | [Link](https://www.targetedonc.com/view/fda-grants-accelerated-approval-to-infigratinib-for-fgfr2-gastric-cancer-and-gea) |
| Epi proColon (ecd-kit-2) | vendor | Epigenomics | New Day Diagnostics. Epigenomics AG sold its US assets, including Epi proColon, to New Day Diagnostics in late 2022. | [Link](https://www.genomeweb.com/business-news/new-day-diagnostics-acquires-epigenomics-us-assets) |

### 🟢 NEW INFORMATION (enhancements, new publications)
| Test | Field | Addition | Source |
|---|---|---|---|
| Galleri (ecd-2) | New Publication | Final results of the PATHFINDER 2 study (n=23,000+) were presented at ESMO 2024, showing the test increased cancer detection 7-fold over standard screening with a PPV of 61.6%. | [Link](https://www.grail.com/press-releases/grail-pathfinder-2-results-show-galleri-multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings/) |
| clonoSEQ (mrd-19) | Clinical Trial Update | Adaptive Biotechnologies announced a collaboration with Takeda (Dec 2024) to use clonoSEQ as the MRD endpoint in a Phase 3 trial for an investigational therapy in multiple myeloma. | [Link](https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-collaboration-takeda-utilize) |
| Signatera (mrd-7) | New Publication | The Phase 3 ALTAIR trial results (ESMO 2024) showed Signatera-guided treatment de-escalation in Stage II colon cancer was non-inferior to standard-of-care adjuvant chemo, potentially sparing 15% of patients from unnecessary treatment. | [Link](https://www.onclive.com/view/circulate-japan-altair-trial-supports-ctdna-guided-de-escalation-of-act-in-stage-ii-colon-cancer) |
| Freenome CRC (ecd-6) | Commercial Update | Freenome entered an exclusive licensing agreement with Exact Sciences (Aug 2024) for its CRC blood test in the U.S. This positions the test for a major commercial launch post-FDA approval. | [Link](https://www.freenome.com/newsroom/freenome-and-exact-sciences-enter-into-exclusive-licensing-agreement-for-freenomes-blood-based-colorectal-cancer-screening-test-in-the-u-s/) |
| Tempus xT CDx (tds-5) | Reimbursement Update | Received ADLT (Advanced Diagnostic Laboratory Test) status from CMS in September 2024, setting a Medicare reimbursement rate of $4,500. | [Link](https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling) |

### 🆕 MISSING TESTS (should be added)
| Test | Vendor | Category | Key Info | Source |
|---|---|---|---|---|
| **Agilent Resolution ctDx FIRST** | Agilent | TDS (IVD Kit) | FDA-approved liquid biopsy CDx for KRAS G12C-mutated NSCLC to identify patients for sotorasib (LUMAKRAS). Competes with Guardant360/F1 Liquid CDx. | [Link](https://www.fda.gov/medical-devices/recently-approved-devices/resolution-ctdx-first-p210023) |
| **Adela MCED** | Adela | ECD (MCED) | MCED test using cfMeDIP-seq (methylation-enriched sequencing). Published validation in a large cohort (Nature 2024) showing strong performance. Competitor to Galleri. | [Link](https://www.adelabio.com/science/publications/) |
| **PanSeer** | Singlera Genomics | ECD (MCED) | Methylation-based MCED test with published data in Nature Communications demonstrating detection of 5 cancer types up to 4 years before conventional diagnosis. | [Link](https://www.singlera.com/technology/) |
| **ArcherDX PCM** | Invitae / Labcorp | MRD | Tumor-informed MRD assay using Anchored Multiplex PCR (AMP). Acquired by Invitae, then assets acquired by Labcorp. Has FDA Breakthrough Device Designation. Complements Invitae PCM (mrd-16) in the Labcorp portfolio. | [Link](https://www.invitae.com/en/physician/personalized-cancer-monitoring) |
| **OncoK9 / OncoK9-V** | PetDx / Antech | TDS (Veterinary) | While not for humans, this is the leading liquid biopsy for cancer detection in dogs. Its market success and technology are relevant to the broader liquid biopsy landscape. | [Link](https://petdx.com/onkok9/) |

### ✅ VERIFIED ACCURATE
The following tests were spot-checked and their data appears to be current, accurate, and well-cited as of December 2024.
- **Shield (ecd-1):** FDA approval date, PMA number, and performance data from the ECLIPSE trial are correct. Internal consistency between sensitivity, specificity, and PPV/NPV is confirmed.
- **Cologuard Plus (ecd-3):** FDA approval date and performance data from the BLUE-C trial are correct and recent.
- **MI Cancer Seek (tds-9):** Recent FDA approval (Nov 2024) and associated CDx claims are accurately reflected.
- **Guardant LUNAR (mrd-13):** The data correctly identifies this as an RUO platform and accurately cites the key validation study (Parikh et al. 2021), correctly distinguishing landmark vs. longitudinal performance.
- **NavDx (mrd-14):** Regulatory status (LDT with ADLT), Medicare coverage details, and performance metrics for HPV-driven cancers are accurate and well-supported by the provided citations.